$46.50
2.58%
Nasdaq, Sep 05, 10:09 pm CET
ISIN
US80105N1054
Symbol
SNY

Sanofi Sponsored ADR Stock price

$46.50
-1.34 2.80% 1M
-12.65 21.39% 6M
-1.73 3.59% YTD
-11.74 20.16% 1Y
+6.42 16.02% 3Y
-2.97 6.00% 5Y
-1.95 4.02% 10Y
+3.45 8.00% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
+1.17 2.58%
ISIN
US80105N1054
Symbol
SNY
Industry

Key metrics

Basic
Market capitalization
$112.8b
Enterprise Value
$121.0b
Net debt
$8.1b
Cash
$18.0b
Shares outstanding
1.3b
Valuation (TTM | estimate)
P/E
4.4 | 5.0
P/S
1.8 | 2.1
EV/Sales
1.9 | 2.3
EV/FCF
9.1
P/B
1.4
Dividends
DPS
$2.20
Yield 1Y | 5Y
4.7% | 4.0%
Growth 1Y | 5Y
7.8% | 5.3%
Payout 1Y | 3Y
39.3% | 32.5%
Increased
2 Years
Financials (TTM | estimate)
Revenue
$63.0b | $53.0b
EBITDA
$16.2b | $16.9b
EBIT
$14.0b | $13.4b
Net Income
$12.9b | $11.7b
Free Cash Flow
$13.3b
Growth (TTM | estimate)
Revenue
34.5% | 2.0%
EBITDA
38.8% | 36.5%
EBIT
46.1% | 31.5%
Net Income
160.9% | 79.9%
Free Cash Flow
167.4%
Margin (TTM | estimate)
Gross
71.9%
EBITDA
25.7% | 31.9%
EBIT
22.2%
Net
20.5% | 22.1%
Free Cash Flow
21.2%
Financial Health
Equity Ratio
58.4%
Return on Equity
7.2%
ROCE
12.4%
ROIC
10.8%
Debt/Equity
0.3
More
EPS
$10.5
FCF per Share
$10.6
Short interest
0.2%
Employees
83k
Rev per Employee
$630.0k
Show more

Is Sanofi Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Sanofi Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Sanofi Sponsored ADR forecast:

21x Buy
72%
7x Hold
24%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Sanofi Sponsored ADR forecast:

Buy
72%
Hold
24%
Sell
3%

Financial data from Sanofi Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
62,987 62,987
34% 34%
100%
- Direct Costs 17,730 17,730
24% 24%
28%
45,256 45,256
39% 39%
72%
- Selling and Administrative Expenses 12,485 12,485
32% 32%
20%
- Research and Development Expense 11,131 11,131
43% 43%
18%
16,167 16,167
39% 39%
26%
- Depreciation and Amortization 2,185 2,185
5% 5%
3%
EBIT (Operating Income) EBIT 13,982 13,982
46% 46%
22%
Net Profit 12,892 12,892
161% 161%
20%

In millions USD.

Don't miss a Thing! We will send you all news about Sanofi Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanofi Sponsored ADR Stock News

Negative
Fast Company
4 days ago
Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab disappointed Wall Street.
Negative
Investors Business Daily
4 days ago
Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.
Negative
Market Watch
4 days ago
Sanofi shares plunged at the market open Thursday as results from a late-stage trial of its experimental drug to treat skin conditions disappointed investors.
More Sanofi Sponsored ADR News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office France
CEO Paul Hudson
Employees 82,878
Founded 1994
Website www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today